ctDNA in Early-Stage Breast Cancer: Prognostic Power vs Clinical Actionability | OncLive Heather A. Parsons, MD, MPH, shares growing evidence for the prognostic value of circulating tumor DNA in early-stage breast cancer.

Is ctDNA ready for primetime in early-stage breast cancer? Heather A. Parsons, MD, MPH, breaks down what's known regarding the prognostic value of ctDNA and how this biomarker could affect clinical practice #gotoPER #MBCC26 #bcsm #oncology www.onclive.com/view/ctdna-i...

Real-World Analysis Highlights Tolerability of T-DXd in HER2-Low Metastatic Breast Cancer Treated in a Community Setting | OncLive T-DXd was associated with low rates of real-world discontinuation in HER2-low metastatic breast cancer.

A real-world analysis showed T-DXd led to toxicity-related discontinuation at rates similar to those from the DESTINY-Breast04 trial in patients with metastatic HER2-low breast cancer treated in the community setting #gotoPER #MBCC26 #bcsm #oncology www.onclive.com/view/real-wo...

Rugo Spotlights Multidisciplinary Insights of Interest at the 43rd Annual Miami Breast Cancer Conference | OncLive Find out which of this year’s Miami Breast presentations are anticipated to be “heard on Friday and used on Monday.”

The 43rd Annual Miami Breast Cancer Conference is underway. To help you prepare, @hoperugo.bsky.social sat down with OncLive to preview some of the top sessions, talks, and workshops headlining this year's meeting #gotoPER #MBCC26 #bcsm #oncology www.onclive.com/view/rugo-sp...

Beyond the Genome: Exploring New Frontiers in NSCLC Management | OncLive Soo-Ryum (Stewart) Yang, MD, discusses biomarkers for ADCs, the actionability of tumor suppressor genes, and the advent of computational pathology.

Beyond the Genome: Exploring New Frontiers in NSCLC Management @mskcancercenter.bsky.social
#gotoPER #lcsm #oncology
www.onclive.com/view/beyond-...

Dr Reckamp on the Future Implications of the PRAGMATICA-LUNG Trial in Lung Cancer Karen L. Reckamp, MD, discusses the feasibility of future pragmatic clinical trials for patients with lung cancer.

WATCH: Karen L. Reckamp, MD, discusses the feasibility of future pragmatic clinical trials for patients with lung cancer. #ILCC2025 #gotoPER #lcsm
www.onclive.com/view/dr-reck...

Dr Das on Updates to the Standard First-Line Treatment Paradigm for ES-SCLC Millie Das, MD, discusses first-line standards of care for patients with extensive-stage and limited-stage small cell lung cancer.

WATCH: Millie Das, MD, discusses first-line standards of care for patients with extensive-stage and limited-stage small cell lung cancer. #gotoPER #ILCC2025 #lcsm
www.onclive.com/view/dr-das-...

Thanks to Dr Millie Das for meeting with us during #ILCC2025 to discuss updates to the SCLC treatment paradigm and the management of brain mets in NSCLC! See our site for #lcsm insights from Dr Das and more! #gotoPER
www.onclive.com/conference/i...

Novel Approaches Offer the Potential to Combat Immunotherapy–Refractory NSCLC Hossein Borghaei, DO, MS, discusses novel approaches to overcoming immunotherapy resistance in patients with non–small cell lung cancer.

Novel Approaches Offer the Potential to Combat Immunotherapy–Refractory NSCLC @foxchasecancer.bsky.social #gotoPER #ILCC2025 #lcsm www.onclive.com/view/novel-a...

A huge thanks to Dr Misako Nagasaka, of @ucirvine.bsky.social, for sitting down with us at #ILCC2025 to talk about the management of NTRK+ and NRG1 fusion+ NSCLC! See our site for more meeting insights! #gotoPER #lcsm
www.onclive.com/conference/i...

Thanks to Dr Karen Reckamp, of @cedarssinaicancer.bsky.social, for stopping by during #ILCC2025 to discuss the management of RET+ NSCLC & novel therapies for patients with NSCLC without actionable mutations. Check out our site for more from the meeting! #gotoPER #lcsm
www.onclive.com/conference/i...

The final day of #ILCC2025 is here! Follow along to see which experts we speak with to close out this year's Congress, and check out our site over the next few days for even more exclusive lung cancer insights. #gotoPER #lcsm
www.onclive.com/conference/i...

Dr Jänne on Second-Line Treatment Evolutions in EGFR-Mutated NSCLC Pasi A. Jänne, MD, PhD, discusses changes to the second-line treatment paradigm and treatment decision-making factors for patients with EGFR-mutated NSCLC.

WATCH: Pasi A. Jänne, MD, PhD, discusses changes to the second-line treatment paradigm and treatment decision-making factors for patients with EGFR-mutated NSCLC.
@danafarber.bsky.social #ILCC2025 #gotoPER #lcsm
www.onclive.com/view/dr-j-nn...

Thanks to Dr Keriann Van Nostrand, of @ucsdhealth.bsky.social, for sitting down with us at #ILCC2025 to chat about the role of the pulmonologist in lung cancer screening and smoking cessation efforts! Check out our site for more #lcsm insights! #gotoPER
www.onclive.com/conference/i...

Thank you to Dr Percy Lee, of @cityofhope.bsky.social, for speaking with us at #ILCC2025 about radiation techniques for locally advanced and oligometastatic lung cancer! Head to our site for more from the meeting! #gotoPER #lcsm
www.onclive.com/conference/i...

Thanks so much to Dr Pasi Jänne, of @danafarber.bsky.social, for sitting down with us at #ILCC2025 to discuss targeted therapy for locally advanced NSCLC! Check back on our site for exclusive #lcsm perspectives from Dr Jänne and more! #gotoPER
www.onclive.com/conference/i...

Personalizing Treatment for Atypical EGFR-Mutated NSCLC Sukhmani Padda, MD, discusses ways in which evolving treatment paradigms are tailoring treatment to target atypical EGFR alterations in NSCLC.

Personalizing Treatment for Atypical EGFR-Mutated NSCLC @foxchasecancer.bsky.social #ILCC2025 #gotoPER #lcsm
www.onclive.com/view/persona...

Dr Mok on Choosing Between First-Line Therapies for BRAF-Mutant NSCLC Tony S.K. Mok, BMSc, MD, FRCP(C), FHKCP, FHKAM, FASCO, discusses first-line treatment decision-making for patients with BRAF-mutant non–small cell lung cancer.

WATCH: Tony S.K. Mok, BMSc, MD, FRCP(C), FHKCP, FHKAM, FASCO, discusses first-line treatment decision-making for patients with BRAF-mutant non–small cell lung cancer. #ILCC2025 #gotoPER #lcsm
www.onclive.com/view/dr-mok-...

Thanks to Dr Tony Mok for speaking with us at #ILCC2025 about the management of BRAF-mutant NSCLC! Head to our site to see #lcsm insights from Dr Mok and more! #gotoPER
www.onclive.com/conference/i...

Thank you to Dr Martin Dietrich for stopping by during #ILCC2025 to discuss the evolving NSCLC treatment paradigm! Check out our site for more meeting insights! #gotoPER #lcsm
www.onclive.com/conference/i...

Day 1 of the 26th Annual International Lung Cancer Congress is in full swing! Check back throughout the day for exclusive behind-the-scenes updates, and see our site for additional coverage! #gotoPER #ILCC2025 #lcsm
www.onclive.com/conference/i...

Alisertib Plus Endocrine Therapy Is Under Evaluation in HR+/HER2-Negative Metastatic Breast Cancer ALISCA-Breast1 is investigating alisertib plus endocrine therapy in HR-positive, HER2-negative recurrent or metastatic breast cancer.

Alisertib Plus Endocrine Therapy Is Under Evaluation in HR+/HER2-Negative Metastatic Breast Cancer #gotoPER #MBCC25 #bcsm www.onclive.com/view/alisert...

Neratinib Generates CNS Responses Across HER2+ Breast Cancer Brain Metastases Subgroups Neratinib-containing combinations are consistently effective across CNS end points in patients with HER2-positive breast cancer brain metastases.

Neratinib Generates CNS Responses Across HER2+ Breast Cancer Brain Metastases Subgroups #gotoPER #MBCC25 #bcsm www.onclive.com/view/neratin...

Enjoy complimentary CME and breakfast on March 14 at 9:30 AM at the Loews Coronado Bay Resort in the Avalon Room, where you'll learn to implement assessment strategies for accurately diagnosing AHP. Save your spot: bit.ly/3F1DC6u #HTRS2025 #gotoper

SERDs, PROTAC, and CERANs Offer Hope Following ET/CDK4/6 Inhibitor Resistance in Breast Cancer Promising new agents are in development to address the unmet need resulting from resistance to endocrine therapy plus CDK4/6 inhibition in breast cancer.

SERDs, PROTAC, and CERANs Offer Hope Following ET/CDK4/6 Inhibitor Resistance in Breast Cancer @hoperugo.bsky.social @ucsfcancer.bsky.social #gotoPER #MBCC25 #bcsm www.onclive.com/view/serds-p...

Atirmociclib Plus Letrozole Demonstrates Preliminary Efficacy and Safety in HR+/HER2-Negative Metastatic Breast Cancer Preliminary data showed atirmociclib plus letrozole yielded antitumor activity in HR-positive/HER2-negative metastatic breast cancer.

Atirmociclib Plus Letrozole Demonstrates Preliminary Efficacy and Safety in HR+/HER2-Negative Metastatic Breast Cancer @danafarber.bsky.social #gotoPER #MBCC25 #bcsm www.onclive.com/view/atirmoc...

Systemic Therapies Are Now Preferred in Some Patients With HER2+ Breast Cancer Brain Metastases Sara A. Hurvitz, MD, FACP, discusses the growing role of systemic therapy in HER2-positive breast cancer brain metastases.

Systemic Therapies Are Now Preferred in Some Patients With HER2+ Breast Cancer Brain Metastases @fredhutch.bsky.social #gotoPER #MBCC25 #bcsm #oncology www.onclive.com/view/systemi...

Abemaciclib Delivers Consistent Benefit in High-Risk, Early Breast Cancer Regardless of Dose Reductions Patients with high-risk, early breast cancer receiving adjuvant abemaciclib maintained benefit with the agent regardless of dose modification.

Abemaciclib Delivers Consistent Benefit in High-Risk, Early Breast Cancer Regardless of Dose Reductions @bswhealth.bsky.social @texasoncology.bsky.social #MBCC25 #gotoPER #bcsm #oncology
www.onclive.com/view/abemaci...

Meet Scout! Our AI-trained search tool is designed to help answer your clinical questions. There is a display located near the registration desk at #MBCC25 - give it a try and let us know what you think! #gotoPER #bcsm

We're jumping into day 2 of #MBCC25 with some incredible discussions, including a CE-Certified Satellite Symposium Coffee Talk™ on HER2, HER3, and TROP2 in breast cancer care, facilitated by Hope Rugo, MD, and colleagues. Stay tuned for more live updates! #gotoPER #bcsm

Sacituzumab Govitecan Produces Comparable Real-World OS Results, Low Rates of Neutropenia in Metastatic TNBC Sacituzumab govitecan was active with low rates of neutropenia—especially in patients receiving G-CSF—in real-world metastatic TNBC.

Sacituzumab Govitecan Produces Comparable Real-World OS Results, Low Rates of Neutropenia in Metastatic TNBC #gotoPER #MBCC25 #bcsm #oncology www.onclive.com/view/sacituz...